Adversity is less terrifying than hope: RedHill Biopharma Ltd. (RDHL)

RedHill Biopharma Ltd. (NASDAQ: RDHL) stock fell -6.05% on Friday to $0.91 against a previous-day closing price of $0.97. With 7.45 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.77 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $1.0700 whereas the lowest price it dropped to was $0.9000. The 52-week range on RDHL shows that it touched its highest point at $11.18 and its lowest point at $0.62 during that stretch. It currently has a 1-year price target of $12.50. Beta for the stock currently stands at 1.89.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RDHL was up-trending over the past week, with a rise of 4.13%, but this was down by -0.52% over a month. Three-month performance dropped to -45.17% while six-month performance fell -63.88%. The stock lost -86.98% in the past year, while it has lost -64.72% so far this year. A look at the trailing 12-month EPS for RDHL yields -1.90 with Next year EPS estimates of 0.03. For the next quarter, that number is -0.03. This implies an EPS growth rate of -0.50% for this year and 46.50% for next year.

Float and Shares Shorts:

At present, 52.52 million RDHL shares are outstanding with a float of 34.99 million shares on hand for trading. On Jul 14, 2022, short shares totaled 2.07 million, which was 3.89% higher than short shares on Jun 14, 2022. In addition to Mr. Dror Ben-Asher as the firm’s Co-Founder, Chairman & CEO, Mr. Micha Ben-Chorin serves as its Chief Financial Officer.

Institutional Ownership:

Through their ownership of 12.66% of RDHL’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 6.14% of RDHL, in contrast to 5.65% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in RDHL with 3.34% of the stake, Disciplined Growth Investors, Inc holds 1,950,002 shares worth 1,950,002. A second-largest stockholder of RDHL, Medical Strategy GmbH, holds 1,351,260 shares, controlling over 2.32% of the firm’s shares. ARK Investment Management LLC is the third largest shareholder in RDHL, holding 1,045,023 shares or 1.79% stake. With a 2.01% stake in RDHL, the FCP Medical – BioHealth is the largest stakeholder. A total of 1,169,340 shares are owned by the mutual fund manager. The ARK Israel Innovative Technology, which owns about 1.81% of RDHL stock, is the second-largest Mutual Fund holder. It holds 1,057,731 shares valued at 0.92 million. APO Medical Opportunities holds 0.65% of the stake in RDHL, owning 380,687 shares worth 0.33 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RDHL since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With RDHL analysts setting a high price target of $11.00 and a low target of $4.50, the average target price over the next 12 months is $8.83. Based on these targets, RDHL could surge 1108.79% to reach the target high and rise by 394.51% to reach the target low. Reaching the average price target will result in a growth of 870.33% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. RDHL will report FY 2022 earnings on 02/23/2023. Analysts have provided yearly estimates in a range of -$0.08 being high and -$0.08 being low. For RDHL, this leads to a yearly average estimate of -$0.08. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. RedHill Biopharma Ltd. surprised analysts by $0.27 when it reported -$0.03 EPS against a consensus estimate of -$0.30. The surprise factor in the prior quarter was -$0.07. Based on analyst estimates, the high estimate for the next quarter is -$0.02 and the low estimate is -$0.02. The average estimate for the next quarter is thus -$0.02.

Leave a Comment

Your email address will not be published.